Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia.
Indian Pediatr
;
1995 Aug; 32(8): 855-61
Article
Dans Anglais
| IMSEAR
| ID: sea-9827
ABSTRACT
OBJECTIVES:
To assess efficacy and safety of oral iron chelating agent deferiprone (DFP) in patients with beta thalassemia and hemoglobin E-beta thalassemia.DESIGN:
Non-randomized study.SETTING:
Hematology Out-Patient Department.SUBJECTS:
Forty-one patients of beta thalassemia and hemoglobin E-beta thalassemia.INTERVENTIONS:
DFP was given to 20 patients, 10 patients of beta thalassemia and 10 with hemoglobin E-beta thalassemia; the rest were taken as controls.RESULTS:
A significant fall in serum ferritin was observed in the study group along with rise in urinary iron excretion (p < 0.05). Adverse effects of DFP were nausea and vomiting (30%), significant arthropathy requiring stopping of the drug (30%), and reversible neutropenia in one patient. All these complications could be managed easily with medical supervision and no death or permanent disability was seen.CONCLUSIONS:
DFP is an effective and fairly well tolerated oral iron chelating agent. The side effects that occur can be tackled easily if monitored properly.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Pyridones
/
Femelle
/
Humains
/
Mâle
/
Hémoglobine E
/
Chélateurs
/
Enfant
/
Enfant d'âge préscolaire
/
Administration par voie orale
/
Adolescent
Type d'étude:
Essai clinique contrôlé
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
Indian Pediatr
Année:
1995
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS